Get the Stockscreener App
73.86
3.67%
-2.815
Oruka Therapeutics Inc stock is traded at $73.86, with a volume of 433.24K.
It is down -3.67% in the last 24 hours and down -19.89% over the past month.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
See More
Previous Close:
$76.68
Open:
$75.53
24h Volume:
433.24K
Relative Volume:
0.53
Market Cap:
$4.89B
Revenue:
Net Income/Loss:
$-116.25M
P/E Ratio:
-30.89
EPS:
-2.3912
Net Cash Flow:
$-91.19M
1W Performance:
-4.42%
1M Performance:
-19.89%
6M Performance:
+12.68%
1Y Performance:
+164.65%
1-Day Range:
$73.86
$77.89
1-Week Range:
$75.41
$82.95
52-Week Range:
$24.88
$115.52
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
73.86 | 4.89B | 0 | -116.25M | -91.19M | -2.3912 |
VRTX
Vertex Pharmaceuticals Inc
|
509.86 | 129.23B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.75 | 94.92B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.00 | 82.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.32 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.60 | 42.04B | 5.76B | 514.49M | 1.10B | 4.4813 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Piper Sandler | Overweight |
| Nov-13-25 | Initiated | Jefferies | Buy |
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Barclays | Overweight |
| May-22-25 | Initiated | BTIG Research | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Oruka Therapeutics senior vice president Arjun Agarwal sells $805,888 in stock - Investing.com
Form 4 Oruka Therapeutics Inc: Arjun Agarwal (Senior Vice President, Finance) For: 12 October - Investing.com India
Form 4 Oruka Therapeutics Inc: Arjun Agarwal (Senior Vice President, Finance) For: 12 October - Investing.com UK
Oruka Therapeutics' Arjun Agarwal Executes Option Exercises and Sells Nearly 10,000 Shares - Kalkine Media
An officer proposes selling 9,999 Oruka Therapeutics (ORKA) shares acquired through stock options. - Stock Titan
Form 4 Oruka Therapeutics Inc For: 2 October By Investing.com - Investing.com South Africa
Oruka Therapeutics (ORKA) CEO Lawrence Klein Sells 25,000 Shares - GuruFocus
Oruka Therapeutics CEO Klein sells $2.09m in stock - Investing.com
Form 4 Oruka Therapeutics Inc For: 2 October By Investing.com - Investing.com Nigeria
25,000 shares from a stock-option exercise are proposed for sale at Oruka Therapeutics (NASDAQ: ORKA). - Stock Titan
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing - GlobeNewswire Inc.
Oruka Therapeutics general counsel Paul Quinlan sells $936k in stock - Investing.com Nigeria
Form 4 Oruka Therapeutics Inc For: 22 September By Investing.com - Investing.com Nigeria
Form 4 Oruka Therapeutics Inc For: 22 September By Investing.com - Investing.com Canada
Oruka Therapeutics general counsel Paul Quinlan sells $936k in stock - Investing.com Canada
Form 4 Oruka Therapeutics Inc For: 22 September - Investing.com India
Oruka Therapeutics general counsel Paul Quinlan sells $936k in stock - Investing.com
Details on Warrant Exercise and Subsequent Share Sales by Oruka Therapeutics' General Counsel - Kalkine Media
Oruka Therapeutics SVP Arjun Agarwal Sells 533 Shares Under Rule 10b5-1 Plan - Kalkine Media
Oruka Therapeutics SVP Arjun Agarwal sells $51,034 in ORKA stock - Investing.com
Oruka Therapeutics SVP Arjun Agarwal sells $51,034 in ORKA stock By Investing.com - Investing.com South Africa
Oruka Therapeutics SVP Arjun Agarwal sells $51,034 in ORKA stock By Investing.com - Investing.com Nigeria
Oruka Therapeutics (NASDAQ: ORKA) insider plans new share sale after recent 10b5-1 trades - Stock Titan
Oruka Therapeutics SVP Agarwal sells over $926k in common stock By Investing.com - Investing.com South Africa
Oruka Therapeutics SVP Agarwal sells over $926k in common stock - Investing.com India
Oruka Therapeutics general counsel Paul Quinlan sells $99,442 in stock - Investing.com
Oruka Therapeutics CEO Lawrence Klein sells $234,680 in ORKA stock - Investing.com
Oruka Therapeutics general counsel Paul Quinlan sells $99,442 in stock By Investing.com - Investing.com Canada
Oruka Therapeutics COO Sandler sells $86,713 in common stock - Investing.com
Oruka (ORKA) legal chief sells shares to cover RSU taxes - Stock Titan
Oruka (ORKA) finance SVP sells 10K shares after option exercises - Stock Titan
Oruka Therapeutics to Attend Morgan Stanley Global Healthcare Conference - Bitget
Morgan Stanley's New York healthcare conference includes Oruka - Stock Titan
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference - GlobeNewswire
About Oruka Therapeutics Inc aStock - Coinbase
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy - Investing.com UK
UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Oruka Therapeutics CEO Klein sells $6.8m in stock By Investing.com - Investing.com South Africa
Oruka Therapeutics COO Laura Sandler sells $459,101 in stock By Investing.com - Investing.com South Africa
Oruka Therapeutics(ORKA.US) Officer Sells US$6.89 Million in Common Stock - Moomoo
Oruka Therapeutics COO Laura Sandler sells $459,101 in stock By Investing.com - Investing.com Nigeria
Oruka Therapeutics CEO Klein sells $6.8m in stock By Investing.com - Investing.com Nigeria
Oruka Therapeutics COO Laura Sandler sells $459,101 in stock - Investing.com
Oruka Therapeutics CEO Klein sells $6.8m in stock - Investing.com
Oruka Therapeutics COO Laura Sandler sells $459,101 in stock - Investing.com India
Oruka Therapeutics COO Laura Sandler sells $459,101 in stock By Investing.com - Investing.com Canada
Oruka Therapeutics CEO Klein sells $6.8m in stock - Investing.com UK
Insider at Oruka Therapeutics (ORKA) plans stock sale from option exercise - Stock Titan
Oruka Therapeutics (NASDAQ: ORKA) officer lines up another stock sale after two summer trades - stocktitan.net
Oruka Therapeutics Inc Stock (ORKA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oruka Therapeutics Inc Stock (ORKA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Arjun Agarwal | Officer |
Oct 12 '26 |
Proposed Sale |
82.11 |
9,999 |
821,018 |
0 |
| Agarwal Arjun | Senior Vice President, Finance |
Oct 12 '26 |
Sale |
80.60 |
9,999 |
805,889 |
14,219 |
| Klein Lawrence Otto | Chief Executive Officer |
Oct 01 '26 |
Option Exercise |
7.80 |
25,000 |
195,000 |
948,128 |
| Klein Lawrence Otto | Chief Executive Officer |
Oct 01 '26 |
Sale |
83.62 |
25,000 |
2,090,593 |
923,128 |
| LAWRENCE KLEIN | Director |
Oct 01 '26 |
Proposed Sale |
83.29 |
25,000 |
2,082,250 |
0 |
| Arjun Agarwal | Officer |
Sep 21 '26 |
Proposed Sale |
94.96 |
533 |
50,614 |
0 |
| Quinlan Paul T | General Counsel |
Sep 21 '26 |
Option Exercise |
7.80 |
10,000 |
78,000 |
39,995 |
| Agarwal Arjun | Senior Vice President, Finance |
Sep 21 '26 |
Sale |
95.75 |
533 |
51,035 |
14,219 |
| Quinlan Paul T | General Counsel |
Sep 21 '26 |
Sale |
93.64 |
10,000 |
936,417 |
29,995 |
| Quinlan Paul T | General Counsel |
Sep 15 '26 |
Sale |
95.71 |
1,039 |
99,443 |
29,995 |
2.73%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):